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Novel mutations in PIEZO1 cause an autosomal
recessive generalized lymphatic dysplasia with
non-immune hydrops fetalis
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Generalized lymphatic dysplasia (GLD) is a rare form of primary lymphoedema characterized
by a uniform, widespread lymphoedema affecting all segments of the body, with systemic
involvement such as intestinal and/or pulmonary lymphangiectasia, pleural effusions,
chylothoraces and/or pericardial effusions. This may present prenatally as non-immune
hydrops. Here we report homozygous and compound heterozygous mutations in PIEZO1,
resulting in an autosomal recessive form of GLD with a high incidence of non-immune
hydrops fetalis and childhood onset of facial and four limb lymphoedema. Mutations in
PIEZO1, which encodes a mechanically activated ion channel, have been reported with
autosomal dominant dehydrated hereditary stomatocytosis and non-immune hydrops of
unknown aetiology. Besides its role in red blood cells, our ﬁndings indicate that PIEZO1 is also
involved in the development of lymphatic structures.
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G
eneralized lymphatic dysplasia (GLD) is a rare form of
primary lymphoedema characterized by a uniform,
widespread lymphoedema affecting all segments of the
body with systemic involvement such as intestinal and/or
pulmonary lymphangiectasia, pleural effusions, chylothoraces
and/or pericardial effusions1. The lymphatic dysfunction often
presents prenatally as non-immune hydrops fetalis (NIHF) and
the incidence of hydrops is higher than seen in other primary
lymphoedemas. Other clinical features may include facial
dysmorphism, possibly due to in utero oedema.
An autosomal recessive type of GLD has previously been
reported; Hennekam Lymphangiectasia-Lymphoedema syndrome
(HS) (OMIM #235510 and OMIM #616006), caused by
mutations in CCBE1 (refs 2,3) and FAT4 (ref. 4) explaining
o50% of HS cases. Patients with HS typically have full body
oedema including severe facial swelling giving these patients the
very characteristic HS facial features including periorbital
oedema, retrognathia, ﬂat facial proﬁle, high palate, gingival
hypertrophy and microstomia5. The majority of HS patients also
variably have intestinal lymphangiectasia, seizures, microcephaly,
mild growth retardation and intellectual disability.
We have identiﬁed a further form of recessive GLD
characterized by a high incidence of NIHF with either demise
or complete resolution of the neonatal oedema but childhood
onset of lymphoedema with or without systemic involvement.
There is often the presence of mild facial oedema but facial
cellulitis is a common and serious complication of this disorder.
The facial features are not suggestive of HS and this cohort has
normal intelligence and no seizures.
We performed a sequencing study and identiﬁed unreported
variants in a mechanically activated ion channel, PIEZO1, that
co-segregate with the disease status in the six families under
study. The mutations were shown by western blot to affect
expression of PIEZO1 in affected individuals. Heterozygous
mutations in PIEZO1 are reported to cause a rare form of
haemolytic anaemia called dehydrated hereditary stomatocytosis
(DHS), and careful examination of the blood ﬁlms from three of
the affected patients and ﬁve carrier parents have demonstrated
subtle changes consistent with abnormalities of the red cell
membrane. This suggests a phenotypic overlap between these two
entities, but more analysis would be required to fully elucidate the
extent of this. However, it appears that PIEZO1 is not only
important for red blood cell (RBC) stability, but also in lymphatic
development.
Results
Patient selection. Two sibling pairs and one sporadic case of
GLD with no identiﬁable mutations in CCBE1 were initially
identiﬁed for analysis. NIHF was documented in two of these
families (GLD2 and GLD3), with in utero demise of one sibling
(GLD2:II.1, Table 1). Postnatally, the oedema associated with the
hydrops resolved completely but the patients re-presented with
lymphoedema of the peripheries in early childhood (Table 1).
Two of the affected individuals suffer from intermittent, severe
facial swelling due to recurrent cellulitis. This is rarely seen in
other forms of primary lymphoedema. There was no history of
haemolytic anaemia, and the immune proﬁles for both siblings
were entirely normal.
The phenotype is distinct from Hennekam syndrome as none
of our GLD patients had the dysmorphic features associated with
HS, nor the learning disabilities or seizures, nor was the swelling
severe (Fig. 1).
Exome sequencing was performed on the three probands. No
variants were found in FAT4. Applying an autosomal recessive
inheritance model requiring at least one previously unobserved
rare homozygous, or two rare heterozygous, protein altering
variants in the same gene in all three individuals highlighted
PIEZO1 as the only candidate gene matching these criteria.
On follow-up with Sanger sequencing, we found the variants
co-segregate with the disease status in the families
(Supplementary Fig. 1).
Sanger sequencing. Additional GLD probands (n¼ 10) with a
similar phenotype were sequenced for all PIEZO1 coding exons
and their associated splice sites. Variants were identiﬁed in three
of these probands (Table 1), one of which was the nonsense
mutation (c.G4888T; p.E1630X) also observed in family GLD1.
The variants were assessed in all available relatives, and were
found to co-segregate with the GLD phenotype (Supplementary
Fig. 1). Two missense variants, c.C2815A and c.C7374G,
in GLD6:II.1 were inherited from the mother (GLD6:I.2) and
at present it is unclear which is responsible for the disease
phenotype. In total, we identiﬁed 10 PIEZO1 variants in 6 families
(Supplementary Fig. 2). The 2 variants in cis in GLD6:II.1 have
been observed (rs201226914 and rs202127176, respectively) with
a minor allele frequency of 0.0002, however, none of the rest were
present in dbSNP, or have been identiﬁed by the 1000 Genomes
Project or observed in a cohort of 900 control samples.
Variant analysis suggests they are pathogenic. The ﬁve missense
mutations alter evolutionarily conserved amino acid residues
(Supplementary Fig. 3) and are predicted to have a damaging
effect on protein function according to MutationTaster6; all are
located within the C-terminal domain of the molecule except
p.L939M (Supplementary Fig. 2). The two splice-site mutations
are predicted in HSF7 and MutationTaster to have signiﬁcant
impact on the splicing of the transcript. Analysis of
complementary DNA (cDNA) from various family members of
GLD3 and GLD4 showed two fragments of differing size,
indicating splicing is being affected. The c.3796þ 1G4A
variant in GLD3 causes skipping of exon 26 (Supplementary
Fig. 4), and the c.1669þ 1G4A variant in GLD4 leads to the
inclusion of intron 13–14 (Supplementary Fig. 5). Western blot
results of the c.3796þ 1G4A variant in GLD3 showed a
reduction in PIEZO1 expression levels (Fig. 2, Supplementary
Fig. 6). The three nonsense mutations are predicted to lead to
premature termination of the protein. No truncated PIEZO1
protein products were identiﬁed in western blot analysis in
GLD1:II.3 and GLD2:II.2 (Fig. 2, Supplementary Fig. 6),
suggesting that the truncated protein is not stable and therefore
degraded.
Blood results show mild abnormalities. Heterozygous variants
in PIEZO1 are associated with DHS. Careful inspection of blood
ﬁlms from our affected individuals demonstrates occasional
stomatocytes and spherocytes (Fig. 3a, Supplementary Fig. 7).
The red cell abnormalities are subtle but convincing. Even fewer
stomatocytes are also observed in carriers (for example, GLD5:I.2
heterozygous for p.E1630X, Supplementary Fig. 7a). It is also
noticeable that the two affected individuals in GLD4 show quite
marked spherocytosis (Supplementary Fig. 7c,d) but the
blood ﬁlm from their carrier mother was unremarkable with
only occasional spherocytes (Supplementary Fig. 7b). All were
asymptomatic, and blood test results are summarized in
Supplementary Table 1.
Lymphoscintigraphy. Four of the patients have had lympho-
scintigraphy, two of all four limbs and two of the lower limbs. The
lymph scan images show striking consistency and symmetry
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(Fig. 3). In the lower limbs, all the patients have deep rerouting as
demonstrated by the popliteal lymph node uptake8. There is also
superﬁcial rerouting through the skin. The rerouting suggests
failure of superﬁcial lymphatic collector function.
Discussion
PIEZO1 is a calcium permeable mechanically activated ion
channel9,10 and is found in the plasma membrane of various cell
types. Mechanotransduction is important for many physiological
processes in the body and is also vital for regulation of embryonic
development. In mouse, Piezo1 mRNA abundance increased
gradually from E9.5 to E15.5 and was sustained through to
birth11.
A haematologic phenotype has been observed in morpholino
knockdown of piezo1 in zebraﬁsh12. Various mouse models are
embryonic lethal when Piezo1 is completely inactivated, but
the heterozygous mice are viable and fertile13,14. Vascular
remodelling was less organized and with a signiﬁcantly lower
number of major vessels, indicating that Piezo1 has an important
role during the development of the blood vasculature. There is
also evidence that PIEZO1 has a role during the development of
the lymphatic vasculature, as it was observed in lymphatic vessels
of the peritoneum in human foetal tissue at 17 weeks of
gestation11.
PIEZO1 is already associated with another human disease;
DHS with or without pseudohyperkalaemia and/or perinatal
oedema (OMIM #194380)15. DHS is an autosomal dominant,
pleiotropic syndrome with signiﬁcant inter and intra familial
variation11,16,17. DHS patients typically present with mild to
moderate haemolytic anaemia characterized by increased
cation leak from red cells, causing erythrocyte dehydration.
Pseudohyperkalaemia occurs as potassium leaks from the red
cells. Splenomegaly, jaundice and NIHF variably occur, the NIHF
being transient and not related to anaemia18. The majority of
DHS variants described in PIEZO1 is missense and predicted as
gain-of-function11, leading to altered channel kinetics. This could
explain the increased permeability of erythrocyte membranes to
cations, causing the clinical presentation of haemolysis in DHS
patients17,19.
Table 1 | Clinical and genetic ﬁndings in GLD patients with PIEZO1 mutations.
Genotyping Antenatal
history
Neonatal
history
Lymphoedema (postnatal
and onwards)
Additional clinical features
ID Gender Age Nucleotide
variant
Exon Protein
alteration
NIHF PH Oedema Onset Limbs Face Dysmorphic
features
Other comments
GLD1 II.2* M 26 c.G4888Tw 36 p.E1630X — — — 6 years 4 limbs Y Micrognathia Recurrent facial
cellulitis, DVT,
genital oedema
II.3 F 34 c.G4888Tw 36 p.E1630X N N N 9 years 4 limbs (Y) N CT and Pl E at age
2 years, recurrent
cellulitis in face and
LL, varicose veins
GLD2 II.1 M NA c.G2263T
c.C6682T
17
46
p.E755X
p.Q2228X
Pl E,
A, S
Y NA NA NA NA NA Died in utero at 34
weeks, amyoplasia
of diaphragm
II.2* M 9 c.G2263T
c.C6682T
17
46
p.E755X
p.Q2228X
Pl E Y Mild
generalized
oedema
with Pl E
At birth 4 limbs (Y) Periorbital
oedema,
cupped
simple ears,
epicanthic
folds,
micrognathia
ASD, GR, CT, short
stature, pectus
excavatum, genital
oedema,
splenomegaly
GLD3 II.1* F 16 c.3796þ 1G4A
c.G6511T
26i
45
Donor
splice site
p.V2171F
Pl E, A — Y (but
resolved
rapidly)
6 years (4 limbs)
L LL
(Y) N GR, intestinal
lymphangiectasia,
granuloma annulare
scoliosis. Oedema
improved on low fat
diet
GLD4 II.1 F NA No DNA
available
— — Pl E,
severe
— Generalized
oedema
At birth 4 limbs Y N Died at age 4 weeks
II.2 F 14 c.1669þ 1G4A
c.C7289T
13i
50
Donor
splice site
p.P2430L
Pl E Y L foot pedal L LL at
birth, R
LL 10
years
B LL (Y) Epicanthic
folds
Cellulitis  3
II.3 F 12 c.1669þ 1G4A
c.C7289T
13i
50
Donor
splice site
p.P2430L
Mild — Oedema
resolved on
day 1
R LL 4y
L LL 8
years
B LL (Y) Epicanthic
folds
Cellulitis  2 LL
Cellulitis  1 face
GLD5 II.2 M 3.5 c.G4888Tw 36 p.E1630X N Y Head and
neck
swelling,
hydroceles
At birth (4 limbs) Y N Intermittent facial
cellulitis, bilateral
sensorineural
deafness,
hypothyroidism,
mild developmental
delay
GLD6 II.1 F 3.5 c.C7366T
c.C7374G/
c.C2815A
51
51/
21
p.R2456C
p.F2458L/
p.L939M
Pl E,
A, S
Y Generalized
oedema at
birth, CT
None NA NA Webbed
neck,
periorbital
oedema,
‘prune’ belly
GR, hypothyroid at
birth
A, ascites; ASD, atrial septal defect; B, bilateral; CT, chylothorax/chylothoraces; DVT, deep vein thrombosis; F, female; GR, gastro-esophageal reﬂux; L, left; LL, lower limb, M, male; N, no; NIHF,
non-immune hydrops fetalis; PH, polyhydramnios; Pl E, bilateral pleural effusions; R, right; S, skin oedema; Y, yes; —, not available; NA, not applicable.
Brackets indicate that swellings have been recorded for that segment in the medical notes, but are currently resolved.
*Exome sequenced.
whomozygous variant.
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Typically, haematology results for DHS patients show evidence
of mild to moderate haemolysis, with normal or reduced
haemoglobin and reticulocytosis, with variable numbers of
stomatocytes seen on the blood ﬁlm16. Hyperkalaemia is often
recorded if there is a signiﬁcant delay between venesection and
analysis. On close inspection, haematological analysis in our GLD
cases show evidence of a mild, asymptomatic haemolytic anaemia
with more subtle changes than that seen in DHS, and with no
documented pseudohyperkalaemia, although the number of cases
is too small to clearly link genotype and phenotype. It is not clear
why red cells adopt a stomatocytic shape in conjunction with
increased cation leak, and the spherocytes seen in one family
(GLD4) are likely to also be due to the PIEZO1 mutation, and
suggest that some cases of spherocytosis could be caused by
mutations in this gene.
Disorders of the lymphatic system have an important role in
the cause of NIHF, and 15% of NIHF cases are reported to be
due to lymphatic dysplasia20. The NIHF in our GLD cases is
clearly related to a lymphatic phenotype, many of the neonates
had evidence of chylothoraces and presented in childhood
with lymphoedema and an abnormal lymphoscintigraphy.
Figure 1 | Clinical ﬁndings in GLD patients with PIEZO1mutations. Faces of (a) GLD6:II.1 at age 3.5 years, (b) GLD4:II.2 at 14 years and (c) GLD4:II.3 at 12
years, all demonstrating epicanthic folds and no current signs of facial swelling. (d) Hand swelling in subject GLD1:II.3. Foot swellings in (e) GLD4:II.2 at age
3 years and (f) GLD4:II.2 at age 14 years, and (g) subject GLD1:II.3 at age 34 years.
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Figure 2 | PIEZO1 protein expression is defective in GLD patients.
Western blot analysis of PIEZO1 protein expression isolated from RBCs
membranes of a healthy control subject and GLD patients. A second gel
was run in parallel using GAPDH as loading control. The position of
molecular mass markers (in kDa) is indicated to the left of the gel.
GLD1:II.3, homozygous nonsense mutation p.E1630X; GLD2:II.2, compound
heterozygous nonsense mutations p.E755X/p.Q2228X; GLD3:II.1,
compound heterozygous splice site c.3796þ 1G4A and missense p.V2171F
mutations; GLD3:I.1, heterozygous splice site c.3796þ 1G4A mutation;
GLD3:I.2, heterozygous missense p.V2171F mutation.
Figure 3 | Blood analysis and lymphoscintigraphy. (a) Blood ﬁlm showing
occasional stomatocytes (arrows) in GLD1:II.2. Scale bar, 20mm. (b) Lower
limb lymphoscintigraphy in an unaffected subject showing symmetrical
migration of radionuclide through discrete lymph vessels 2 h after injection.
(c) Lower limb lymphoscintigraphy of GLD4:II.3 and (d) four limb
lymphoscintigraphy in GLD1:II.3. The three lymph scans have been aligned
so that injection sites in the feet are all at the bottom of the panel with the
groin area all at the same level at the top of b and c. The injection sites in
the hands in d are the dark areas on either side of the groin region and
axillary lymph nodes are visible at the top of d. The lymph scans of the two
patients (c,d) show distinctive changes with poor uptake of tracer in the
groin and axillae at 2 h, with evidence of rerouting in the lower limbs (seen
as the dark shading of the lower limb). Popliteal lymph nodes (arrows)
show prominent uptake of tracer, which is unusual and represents deep
rerouting of the interstitial ﬂuid.
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The hydrops in the DHS cases are reported to be unrelated to
anaemia18 and therefore not of a haematologic origin. Instead, we
suspect it is highly likely to be lymphatic in origin and a case with
severe generalized oedema and cystic hygromas, suggesting a
lymphatic origin has been reported21.
Interestingly, the variants identiﬁed in this cohort cause a mild
form of DHS in affected individuals and carriers but biallelic
variants have a high incidence of NIHF (7 of the 10 affected
cases). This may be lethal in the perinatal period (n¼ 2).
Survivors may present later with lymphoedema of the peripheries
(mainly lower limbs but also arms (n¼ 4), face (n¼ 3) and
genitalia (n¼ 1)), with or without chylothoraces (n¼ 2) and
intestinal lymphangiectasia (n¼ 1). The recurrence of lymphatic
problems in childhood observed in our GLD patients is
comparable to that seen in Turner syndrome22. Four patients
of our cohort had severe, recurrent facial cellulitis with
signiﬁcant morbidity (high pyrexia and frequent admission to
intensive care).
The high incidence of perinatal oedema in both DHS and GLD
cannot be ignored. Monoallelic variants, presenting with DHS in
a parent but perinatal oedema in the offspring, are not fully
understood23,24, but possible explanations include an unidentiﬁed
variant on the other allele, modiﬁer genes or stochastic events.
DHS patients with biallelic missense mutations have been
reported in one family15. They presented with a more severe
haemolytic phenotype compared with heterozygous family
members, but no pseudohyperkalaemia or perinatal oedema
was observed in that particular family. The literature so far has
not described a lymphatic phenotype in the patients who survived
the perinatal oedema or patients with DHS but this requires
further investigation. This could possibly be explained by the lack
of long term follow-up or ascertainment bias.
Too little is known about PIEZO1 to say whether different
forms of the protein exist for certain key mechanisms or tissues,
thus leading to the DHS and GLD phenotypes. The effects of
these PIEZO1 mutations are signiﬁcantly more severe prenatally,
with complete resolution of the oedema after birth in some cases.
This must reﬂect on the speciﬁc role of PIEZO1 on the
lymphatics. The lymphatics undergo a signiﬁcant transformation
at birth under the effect of glucocorticoids25. Perhaps PIEZO1 is
required to maintain the lymphatics in the foetal state but not
required to such a degree after birth. More investigations are
needed to fully understand the role of PIEZO1 in GLD, as well
as DHS.
In summary, we have identiﬁed PIEZO1 mutations that cause
an autosomal recessive form of GLD associated with NIHF and
chronic peripheral primary lymphoedema. Together with CCBE1
and FAT4, this is the third gene to be associated with GLD. The
observation of lymphoedema provides evidence of a role for
PIEZO1 in the development of lymphatic structures. It remains to
be elucidated how far the established ion channel function of
PIEZO1 can account for the different phenotypical aspects of
DHS and GLD and whether at least some defects are the
consequences of a different role of PIEZO1 during development.
Methods
Patient ascertainment. GLD probands with no identiﬁable mutations in CCBE1
were selected for study. Ethical approval for this study was obtained from the South
West London Research Ethics Committee (REC Ref: 05/Q0803/257). Probands and
their families were ascertained through the Primary Lymphoedema Clinic at
St George’s Hospital, London, UK and written informed consent was obtained
from all participants. All affected individuals and their family members underwent
a detailed clinical examination.
Targeted capture and massive parallel sequencing. For GLD1, sequencing
libraries were made following the protocol from Roche/Nimblegen’s SeqCap EZ
Exome Library v2.0 kit (Roche NimbleGen, Inc). The libraries were then sequenced
on a HiSeq2000 (Illumina), with paired end, 101-bp reads. For GLD2 and GLD3,
whole exome capture was performed using the SureSelect Target Enrichment
System (Agilent). This was followed by sequencing on a HiSeq2000 (Illumina) with
100-bp paired end reads. Sequence reads for all families were aligned to the
reference genome (hg19) using Novoalign (Novocraft Technologies SdnBhd).
Duplicate reads, resulting from PCR clonality or optical duplicates and reads
mapping to multiple locations were excluded from downstream analysis. Depth
and breadth of sequence coverage were calculated with custom scripts and the
BedTools package26.
Variant analysis. All exomes from the three families were passed through the
same variant analysis pipeline. Single-nucleotide substitutions and small indel
variants were identiﬁed and quality ﬁltered within the SamTools software
package27 and in-house software tools28. Variants were annotated with respect to
genes and transcripts with the Annovar tool29. Variants were ﬁltered for novelty by
comparing them with dbSNP135 and 1000 Genomes SNP calls and with variants
identiﬁed in 900 control exomes (primarily of European origin), which were
sequenced and analysed by the method described above for GLD2 and GLD3.
Summary statistics for the exome sequencing is given in Supplementary Tables 2
and 3. First the exomes were checked for variants in FAT4, as none were found the
analysis of the exome-variant proﬁles was then performed under a model of a rare
autosomal recessive disorder; this model required one previously unobserved
homozygous variant for the consanguineous GLD1 or two previously unobserved
heterozygous variants in trans in the same gene for all affected individuals in GLD2
and GLD3.
Conﬁrmation sequencing. Samples of available family members were analysed by
Sanger sequencing for the variants found in their respective proband. Further 10
samples with a GLD phenotype were analysed for sequence variants in all of
PIEZO1, hence primers were designed for the coding regions and associated splice
sites of PIEZO1 using Primer3 software30 (primer sequences in Supplementary
Table 4). PCR products were sequenced using BigDye Terminator v3.1 chemistry
(Life Technologies) and an ABI3130xla Genetic Analyzer (Life Technologies).
Sequencing traces were visually inspected in Finch TV v1.4 (Geospiza Inc, Seattle,
WA, USA) and aligned to a wild-type reference using CLC Sequence Viewer
(CLC bio-Qiagen, Denmark). Identiﬁed variants were checked in dbSNP (http://
www.ncbi.nlm.nih.gov/SNP/), 1000 Genomes Project (http://www.1000genomes.org/)
and in a cohort of 900 control samples for novelty. The variants were also analysed
in either Mutation Taster6 or HSF7 for genetic effect.
RNA/cDNA analysis of splice variants. Blood was collected in PAXgene Blood
RNA tubes and RNA puriﬁed using PAXgene Blood RNA Kit (PreAnalytix). About
500 ng of total RNA was used as template for cDNA generation using RT Super-
script II (Invitrogen). Oligos used for splice variant ampliﬁcation in family GLD3
were exon 26F 50-AACCTCATCAGCGACTTTCTC3-30 and exon 26R 50-ATACG
CTCCATCTGTCTTTTC-30; and in family GLD4 were exon 13F 50-TGGAGCA
TCACCTACCACAG-30 and exon 13R 50-GGCTGTAGTAGACCTGGAAGA-30 .
Western blot. RBCs were isolated from blood and lysed by three cycles of freezing
and thawing in 5mM KH2PO4 containing protease inhibitors. Lysate was
centrifuged at 16,000g for 1 h and membrane fraction was washed three times
in 5mM KH2PO4 containing proteases inhibitors. Membrane fraction was
resuspended in RIPA buffer (20mM Tris HCl pH 7.5, 150mM NaCl, 1% Igepal
CA-630, 0.5% sodium deoxycholate and 0.1% SDS) and centrifuged at 16,000g
for 1 h. Supernatant containing membrane proteins was prepared in urea
buffer (200mM Tris HCl pH 6.8, 5% SDS, 8M urea, 100mM DTT and 0.1%
bromophenol blue). Samples were heated for 10min at 37 oC and loaded in
NuPAGE Novex 3-8 % Tris-Acetate gels with NuPAGE Tris-Acetate SDS
running buffer (Life technologies). Proteins were transferred on a polyvinylidene
diﬂuoride membrane, and PIEZO1 protein was detected with a speciﬁc antibody
(15939-1-AP, Proteintech). GAPDH was used as a loading control and detected
with a speciﬁc antibody (ab8245-100, Abcam). See Supplementary Fig. 6 showing
the uncropped western blots.
Haematology and biochemistry analysis. Available family members and/or
probands of four of the six families had blood analysis including tests for Hb,
reticulocytes, potassium, lactate dehydrogenase and haptoglobin. Blood ﬁlms were
prepared with May–Gru¨nwald–Giemsa stain and examined using light microscopy,
looking speciﬁcally for red cell abnormalities including stomatocytes. Each ﬁlm
was examined by two experienced haematologists. Where possible, we looked
at haematology reports in patient notes for the other families and checked for
evidence of haemolysis.
Lymphoscintigraphy. Lymphoscintigraphy is the imaging of the lymphatic system
by injecting radioactive isotope (technetium-99m) into the web spaces between the
toes and/or ﬁngers and quantiﬁcation of uptake into the inguinal lymph nodes
for foot injections and axillary nodes for hand injection after 2 h with a gamma
camera.
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